argenx, a renowned Netherlands based biotechnology firm, reportedly announced the publication of outcomes from the assessment of its FcRn antagonist, efgartigimod, in a Phase 2 ITP clinical trial, in the American Journal of Hematology.

Wim Parys, M.D., chief medical officer, argenx, reportedly stated that efgartigimod showcased a favorable tolerability and the capability to drive encouraging response rates across a refractory demographic after a limited exposure. Parys further added that the company is thrilled to announce the publication of efgartigimod Phase 2 ITP trial results as a new treatment modality in ITP. The company is now looking forward towards advancing efgartigimod into a global Phase 3 ITP program before 2019 ends, where the company would get the opportunity to dose participants in a long-term setting.

The global Phase 3 program in ITP remains on track to start this month and would assess the intravenous (IV) formulation inside the first clinical trial, ADVANCE, along with an IV induction that would be followed by a SC (subcutaneous) maintenance injection in the second trial, ADVANCE SC.

Additionally, efgartigimod is also presently being evaluated for the treatment of serious autoimmune diseases, including chronic inflammatory demyelinating polyneuropathy (CIDP), generalized myasthenia gravis (gMG) and pemphigus vulgaris (PV).

The ADAPT Phase 3 trial of IV efgartigimod in gMG is in progress with data expected in the last two quarters of 2020. A Phase 2 PoC (proof-of-concept) is also in progress in PV and data is expected in the first two quarters of 2020. Meanwhile, a Phase 2 PoC (proof-of-concept) trial of efgartigimod SC in CIDP is expected to start before the end of 2019.

About argenx:

argenx, is a renowned biopharmaceutical firm. It develops and creates a pipeline of differentiated anti-body therapeutics using its Simple Antibody platform, which is based on the powerful llama immune system. The firm develops a deep pipeline of anti-body therapeutics that focuses on cancer and auto-immune diseases.

It creates antibodies that have the best in class therapeutic potential. It includes: ARGX-111, an antagonist of c-Met; a receptor involved in cell proliferation, metastasis and angiogenesis in multiple solid tumors; ARGX-112, an antigen targeting atopic dermatitis, among others.
 

Source credit: https://www.argenx.com/en-GB/news-internal/argenx-announces-publication-of-efgartigimod-phase-2-primary-immune-thrombocytopenia-trial-results-in-american-journal-of-hematology/30242/